Key Takeaways Viking Therapeutics shares fell over 20% in a month, lagging the industry, sector and S&P 500.Mixed oral VK2735 trial results raised concerns about safety despite achieving study endpoints.Viking faces cash burn, no revenue stream and competition from Eli Lilly and Novo Nordisk.Shares of Viking Therapeutics (VKTX) have lost over 20% in the past month, significantly underperforming the industry’s 1% growth. The stock has also underperformed the sector and the S&P 500 during the same period, as ...